Other News To Note
Tuesday, March 1, 2011
Santaris Pharma A/S, of Hoersholm, Denmark, obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for treating cardiovascular disorders. Financial terms were not disclosed. Santaris intends to use its Locked Nucleic Acid platform to develop a LNA-based drug targeting miR-33.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.